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a  b  s  t  r  a  c  t
Introduction: The presence of anti-CCP is an important prognostic tool of rheumatoid arthritis
(RA). But research is still ongoing on its relationship with disease activity and functional
capacity.
Objectives: To study the relationship between anti-CCP and disease activity, functional
capacity and structural damage indexes, by means of conventional radiography (CR) and
magnetic resonance imaging (MRI), in cases of established RA.
Methods: Cross-sectional study with RA patients with 1–10 disease duration. Participants
underwent clinical evaluation with anti-CCP. Disease activity was assessed using the Clin-
ical  Disease Activity Index (CDAI), and functional capacity through the Health Assessment
Questionnaire (HAQ). CR analysis was carried out by the Sharp van der Heijde index (SvdH),
and MRI analysis by RAMRIS (Rheumatoid Arthritis Magnetic Resonance Image Scoring).
Results: We  evaluated 56 patients, with a median (IqR) age of 55 (47.5–60) years; 50 (89.3%) par-
ticipants were female and 37 (66.1%) were positive for anti-CCP. Medians (IqR) of CDAI, HAQ,
SvdH  and RAMRIS were 14.75 (5.42–24.97) 1.06 (0.28–1.75), 2 (0–8) and 15 (7–35), respectively.
There was no association between anti-CCP and CDAI, HAQ and SvdH and RAMRIS scores.
Conclusion: Our results have not established an association of anti-CCP with the severity
of  disease. To date, we cannot corroborate anti-CCP as a prognostic tool in patients withPlease cite this article in press as: Porto LSS, et al. Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis: a
magnetic resonance imaging study. Rev Bras Reumatol. 2015. http://dx.doi.org/10.1016/j.rbre.2015.07.018
established RA.
© 2015 Elsevier Editora Ltda. All rights reserved.
 Study conducted at the Rheumatoid Arthritis Outpatient Clinic, Service of Rheumatology, Santa Casa de Belo Horizonte, and at the
ost-Graduate Program in Adult Health, Medicine School, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
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O  anti-CCP  não  é  um  marcador  de  gravidade  da  artrite  reumatoide






r  e  s  u  m  o
Introduc¸ão: A presenc¸a do anti-CCP constitui importante ferramenta prognóstica da artrite
reumatoide (AR). Mas, ainda, investiga-se sua relac¸ão com a atividade de doenc¸a e a capaci-
dade funcional.
Objetivos: Estudar a relac¸ão o anti-CCP e os índices de atividade da doenc¸a, de capacidade
funcional e de dano estrutural, através de radiograﬁa convencional (RC) e de ressonância
magnética (RM), em AR estabelecida.
Métodos: Estudo transversal com pacientes com AR, com um a 10 anos de doenc¸a. Os par-
ticipantes foram submetidos à avaliac¸ão clínica com pesquisa do Anti-CCP. A atividade de
doenc¸a foi avaliada através Clinical Disease Activity Index (CDAI) e a capacidade funcional
através do Health Assessment Questionnaire (HAQ). A análise da RC foi feita pelo índice de
Sharp van der Heijde (SmvH) e da RM pelo Sistema de Pontuac¸ão de Imagem por Ressonân-
cia Magnética na Artrite Reumatoide (RAMRIS, Rheumatoid Arthritis Magnetic Resonance
Image Scoring).
Resultados: Foram avaliados 56 pacientes, com mediana (IIq) de idade de 55 (47,5-60) anos,
sendo 50 (89,3%) do sexo feminino e 37 (66,1%) anti-CCP positivos. As medianas (IIq) do
CDAI, do HAQ, de SmvH e do RAMRIS foram de 14,75 (5,42-24,97), 1,06 (0,28-1,75), 2 (0-8) e 15
(7-35), respectivamente. Não houve associac¸ão do anti-CCP com o CDAI, com o HAQ e com
os  escores SmvH e RAMRIS.
Conclusão: Nossos resultados não estabeleceram a associac¸ão do anti-CCP com a gravidade
da  doenc¸a. Até o momento, não podemos corroborar o anti-CCP como uma ferramenta
prognóstica em AR estabelecida.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
The progression of rheumatoid arthritis (RA) brings an evo-
lutionary potential to varying degrees of joint damage and
functional disability. Thus, special attention should be given
to the identiﬁcation of poor prognostic indicator parameters,
because ideally the deﬁnition of therapeutic intensity level
should be based on reliable predictors of severity. It is already
known that some features, when present, are associated with
a worse outcome of the disease, such as the presence of high-
titer rheumatoid factor, smoking and HLA-DRB1.1,2
Regarding the prognostic role of anti-CCP, its association
with disease activity and functional capacity has still not been
clariﬁed, although many  studies suggest that these antibod-
ies are associated with more  severe and erosive disease,3–22
especially in cases of initial RA.9,19–21,23–30 It is worth noting
the methodological heterogeneity of the studies that analyzed
the association of anti-CCP with structural damage. Although
most studies have made use of conventional radiography (CR)
as an evaluation tool, different radiographic score systems
were used. Additionally, only one study also made use of ultra-
sonography (US) in a small subgroup of patients.6 There are no
studies that have used magnetic resonance imaging (MRI) for
this purpose.
This study aimed to investigate the association of anti-Please cite this article in press as: Porto LSS, et al. Anti-CCP antibodies 
magnetic resonance imaging study. Rev Bras Reumatol. 2015. http://dx.do
CCP positivity with disease severity as measured by disease
activity, functional capacity and structural damage, measured
using CR and MRI.Patients  and  methods
This is a cross-sectional study, which involved patients
seen in an outpatient clinic. All participants were diagnosed
with established RA according to the American College of
Rheumatology (ACR – 1987)31 or the American College of
Rheumatology/The European League Against Rheumatism
(ACR/EULAR – 201032) criteria, aged 18 or more  years old and
with 1–10 years of disease duration.
Because of the possibility of performing MRI, patients
with creatinine clearance <60 ml/min/1.73 m2, metal prosthe-
sis users, patients with an inability to access the examination
table, and pregnant women were excluded from the study. On
the other hand, patients with previous surgery and/or fracture
in the hand also were excluded.
The study was approved by the Research Ethics Commit-
tee and, after signing the consent form, patients who  agreed
to participate in the study underwent a clinical evaluation
and completed a speciﬁc questionnaire containing demo-
graphic and clinical data (duration of disease, time elapsed
between onset of symptoms and RA diagnosis, smoking his-
tory, rheumatoid factor status, presence of extra-articular
manifestations, treatment, and CDAI33 and HAQ validated
for Portuguese idiom34). A sample of blood was collected for
anti-CCP survey with the use of second-generation meth-are not a marker of severity in established rheumatoid arthritis: a
i.org/10.1016/j.rbre.2015.07.018
ods: EliA CCPTM ﬂuorenzyme-immunoassay test (Pharmacia
Diagnostics, Germany) and chemiluminescent microparti-
cle assay ARCHITECTTM anti-CCP (Abbott Laboratories, USA).
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Table 1 – Characteristics of the patients.
Variables Measures
Age: Median (IqR) 55 (47.5–60.0)
Females: n (%) 50  (89.3)
Disease duration in years: Median
(IqR)
6  (3–9)
Time elapsed between disease and
diagnosis, in years: Median (IqR)
0  (0–1)
Positive rheumatoid factor: n (%) 31 (55.4)
Positive anti-CCP: n (%) 37 (66.1)
Smoker or former smoker, n (%) 25 (44.6)
Presence of rheumatoid nodules: n (%) 8 (14.3)
Pulmonary involvement: n (%) 6 (10.7)
Presence of Sjögren’s syndrome: n (%) 2 (3.6)
Patients taking corticosteroids: n (%) 49 (87.5)
Patients taking synthetic DMARDs: n
(%)
43  (76.8)
Methotrexate: n (%) 15 (26.8)
Leﬂunomide: n (%) 5 (8.9)
Hydroxychloroquine: n (%) 3 (5.4)







Cyclosporin: n (%) 1 (1.8)
Patients on biological DMARDs: n (%) 11 (19.6)
Adalimumab: n (%) 4 (7.1)
Etanercept: n (%) 2 (3.6)
Inﬂiximab: n (%) 3 (5.4)
Tocilizumab: n (%) 2 (3.6)
Patients without DMARDs: n (%) 2  (3.6)
CDAI: Median: (IqR) 14.7 (5.4–25.0)
Remission (≤2.8): n (%) 8 (14.3)
Remission and low activity (≤10): n
(%)
23 (41)
Moderate activity (>10 ≤22): n (%) 17 (30.4)
High activity (>22): n (%) 16 (28.6)
HAQ: Median (IqR) 1.06 (0.28–1.75)
Normal (=0): n (%) 9 (16.1)
Mild to moderate difﬁculty (>0 and
≤1): n (%)
19  (33.9)
Moderate to severe difﬁculty (>1 and
≤2): n (%)
18  (32.1)
Severe to very severe difﬁculty (>2 and
≤3): n (%)
10  (17.9)
Sharp van der Heijdea
Total: Median (IqR) 2 (0–8)
Erosion: Median (IqR) 1 (0–6)
Joint Space Narrow: Median (IqR) 1 (0–5.5)
RAMRISb
Total: Median (IqR) 15 (7–35)
Erosion: Median (IqR) 8 (1–19)
Bone edema: Median (IqR) 6 (2–14)
Synovitis: Median (IqR) 4 (2–6)
n, number of patients with rheumatoid arthritis; IqR, interquar-
tile range; anti-CCP, anti-cyclic citrullinated peptide antibody;
CDAI, clinical index of disease activity; HAQ, Health Assessment
Questionnaire; RAMRIS, Rheumatoid Arthritis Magnetic Resonancer  e v b r a s r e u m a t o l
atients were divided into two groups, according to test
ositivity and to the reference value of the kit used
>10 U/ml for ﬂuorenzyme-immunoassay and >5 U/ml for
hemiluminescence).
Radiographic evaluation was performed by means of hand
nd wrist CRs in a posterior–anterior view. X-rays carried out
n the period up to three months before or after the data col-
ection were accepted. The SvdH method35 was chosen for an
nalysis of hands and wrists.21
A subgroup of 35 patients was referred for MRI examina-
ion in up to four weeks after the interview; for this purpose,
 GE Signa 1.5 T HDxT system (GE Healthcare, Milwaukee,
I,  USA) was used. For resonance analysis, the RAMRIS36
rotocol of the Outcome Measures in Rheumatoid Arthritis
linical Trials (OMERACT) for wrist and metacarpophalangeal
nalysis was used. The examinations were performed on the
ominant hand, using coronal (T1- and T2-weighted imag-
ng with fat suppression), axial (T1-weighted imaging before
nd after the use of intravenous gadolinium contrast) and
xial and coronal (T1-weighted imaging with fat saturation)
equences.
The MRI  and X-ray analyzes were performed by a single
adiologist who  was unaware of the clinical condition of the
atient. The intraobserver agreement for SvdH score was cal-
ulated, and the intraclass correlation coefﬁcient was 0.958.
e were unable to calculate the intraclass coefﬁcient for RAM-
IS because, to obtain this data, it would be necessary to
alculate the variation component, which resulted in a neg-
tive value. Thus, a decision was made in favor of calculating
he Spearman coefﬁcient, with a value of 0.96.
Storage of data and all statistical analyzes were performed
ith the IBM Statistical Package for Social Sciences soft-
are (SPSS version 19). For categorical variables, frequency
istributions were presented; and for continuous variables,
easures of numerical synthesis were employed. The asso-
iation between categorical variables was analyzed using the
hi-squared or Fisher’s exact test. The normality of contin-
ous variables was veriﬁed by the Shapiro–Wilk test. For
ariables without normal distribution, the analysis was per-
ormed using the nonparametric Mann–Whitney U test. To
erify the association between two non-normal continuous
ariables, the nonparametric Spearman test was used. For this
tudy, a 5% signiﬁcance level was set.
esults
rom August 2011 to August 2013, 56 patients with established
A diagnosis were evaluated. Table 1 summarizes the demo-
raphic, clinical, functional and imaging proﬁles of patients.
The univariate analysis of the association of demographic
nd clinical characteristics with the presence of anti-CCP
howed that this antibody was signiﬁcantly associated with
F (OR = 6.6; 95% CI, 1.9–22.9; p < 0.01) and smoking (OR = 7.8;Please cite this article in press as: Porto LSS, et al. Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis: a
magnetic resonance imaging study. Rev Bras Reumatol. 2015. http://dx.doi.org/10.1016/j.rbre.2015.07.018
5% CI, 1.9–31.6; p < 0.01).
Univariate analysis of anti-CCP association with CDAI,
AQ, SvdH, and RAMRIS are presented in Table 2. As to dis-
ase activity, the CDAI median value was higher in the group of
Image Scoring; DMARDs Disease modifying antirheumatic drugs.
a 55 patients underwent CR.
b 35 patients underwent MRI.
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CDAI, median (IqR) 7.5 (4.2–21.4) 16.2 (5.7–31.4) p = 0.06a
CDAI
Remission and low disease activity, n (%) 11 (47.8) 12 (52.2) p = 0.09b
Moderate and high disease activity, n (%) 8 (24.2) 25 (75.8) OR = 2.7(0.9–9.0)
HAQ, median (IqR) 1 (0.25–1.50) 1.13 (0.31–2.00) p = 0.49a
Sharp van der Heijde
Total: Median (IqR) 1 (0–7) 3.5 (0–8) p = 0.29a
Erosion: Median (IqR) 1  (0–4) 2 (0–6.7) p  = 0.31a
Joint Space Narrow: Median (IqR) 1 (0–4) 1(0–2.7) p = 0.39a
RAMRIS
Total: Median (IqR) 14 (8.5–30.5) 23 (6.7–42.0) p = 0.55a
Erosion: Median (IqR) 8 (2–15) 10 (1–22.2) p = 0.50a
Bone edema: Median (IqR) 5  (2–12.5) 8 (2.7–16) p  = 0.37a
Synovitis: Median (IqR) 3  (1.5–5.5) 4 (3–7.2) p  = 0.20a
n, number of patients; anti-CCP, anti-cyclic citrullinated peptide antibody; CDAI, clinical index of disease activity; HAQ, Health Assessment
Questionnaire; RAMRIS, Rheumatoid Arthritis Magnetic Resonance Image Scoring.
a Mann–Whitney U test.
b Chi-squared test.patients positive for anti-CCP, but this ratio was not signiﬁcant
(p = 0.06). Moreover, the presence of a negative anti-CCP was
not associated with the occurrence of remission or a state of
low disease activity (OR = 2.9; 95% CI, 0.9–9; p = 0.09). HAQ, SvdH
(total, erosion, joint space narrowing) and RAMRIS (total, ero-
sion, bone edema, and synovitis) scores were not associated
with the presence of anti-CCP.
In search of a multivariate model to explain anti-CCP
variable, a logistic regression model was adjusted. All vari-
ables correlating with anti-CCP with p < 0.20 (gender, time of
diagnosis, smoking, rheumatoid factor, extra-articular man-
ifestations, rheumatoid nodules, pulmonary involvement,
CDAI and HAQ) were used in the initial model adjustment. In
the ﬁnal model, anti-CCP was related only with smoking and
rheumatoid factor (p < 0.05). The model indicated that smok-
ers and former smokers are 5.3 times more  likely to have a
positive result for anti-CCP (95% CI, 1.2–22.9) and those with
positive RF are 4.4 times more  likely to have a positive result
for anti-CCP (95% CI, 1.2–16.6). The logistic regression model
is shown in Table 3.
The Spearman correlation coefﬁcient between CDAI andPlease cite this article in press as: Porto LSS, et al. Anti-CCP antibodies 
magnetic resonance imaging study. Rev Bras Reumatol. 2015. http://dx.do
image  (SvdH and RAMRIS) indexes was calculated, and no
association among these was found. Of the 35 patients who
underwent MRI, 13 were in remission or in low-disease activ-
ity (CDAI ≤ 10). Of these, 12 (92.3%) patients had edema and 12
Table 3 – Multivariate logistic regression with respect to anti-CC
Variables Beta Standard error 
Smoking 1.7 0.7 
Rheumatoid factor 1.5 0.7 (92.3%) had synovitis, and in only two of them the synovitis
was >5.0 mm (16.6%). Regarding RAMRIS, the following medi-
ans (IqR) were obtained: Total index, 21 (11.5–34), erosion
score, 9 (3.5–15.1), edema score, 6 (3.5 –12.5) and synovitis
score, 3 (2.1–5.7). Among the 22 (95.6%) patients showing
moderate-to-high activity, 21 (95.6%) patients had edema and
21 patients had synovitis. Regarding RAMRIS, the following
medians (IqR) were obtained: Total index, 13 (6–31), erosion
score, 5 (1–17), edema score, 5 (2–14) and synovitis score, 3.5
(2–6). For all RAMRIS indexes, no statistically signiﬁcant dif-
ference between patients in remission and with low disease
activity versus those at moderate-to high disease activity was
observed.
Discussion
The present study examined the demographic, clinical, func-
tional, and image  characteristics of Brazilian patients with
established RA, in order to determine the relationship of anti-
CCP with severity of disease.
In the study population, anti-CCP positivity reached 66.1%,are not a marker of severity in established rheumatoid arthritis: a
i.org/10.1016/j.rbre.2015.07.018
a rate similar to that found by Silva et al.18 for Brazilian
patients with established RA. RF positivity was 55.4%. This
low prevalence can be explained by the ﬂuctuation of antibody
P.
OR CI 95% OR p-Value
5.3 (1.2–22.9) 0.027
4.4 (1.2–16.6) 0.027
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tr  e v b r a s r e u m a t o l
evels during the course of disease in response to treatment,19
r due to the study design, in which the information on RF
ositivity was based on medical record data. It is known that
nti-CCP and RF tests are related. Studies have shown that
ost patients with RA and with a positive result for RF are
lso positive for anti-CCP.3,19 Thus, our study is consistent
ith the literature.
Smoking is the main environmental process related to RA,
ainly in HLA-DRB1-positive patients, and the citrullination
s induced by tobacco substances - the potential pathophy-
iological mechanism of this process.37 This study showed a
igniﬁcant association between smoking and anti-CCP posi-
ivity. This result is in agreement with that found by Pedersen
t al.,38,39 whose study evaluated various environmental risks
ssociated with anti-CCP and HLA-DRB1, and with the ﬁnd-
ngs of Goeldner et al.,40 who studied the association of
moking with anti-CCP in Brazilian patients with established
A.
The assessment of disease activity in our study was
arried out by CDAI, which correlates well with the other
ssessment indexes.29,33,41 Our results showed that anti-CCP-
ositive patients had a median value of CDAI greater than
nti-CCP-negative patients, but with marginal statistical sig-
iﬁcance (p = 0.06). Our results are in agreement with those of
hoe et al.,29 who  evaluated the association of anti-CCP levels
ith DAS28, SDAI and CDAI activity indexes in patients with
stablished RA, with no signiﬁcant association.
Since the remission or low disease activity state is the
ain therapeutic target,42 we  opted also by an analysis of
nti-CCP association with the occurrence of remission and
ow disease activity. Our results showed that an anti-CCP
egative result was not associated with the occurrence of
emission and low disease activity (p = 0.08). Mota et al.,30 who
valuated Brazilian patients with early RA, found no relation-
hip between negative ﬁndings for anti-CCP and remission by
AS28.
In prospective studies on early RA, Kastbom et al.24 and
önnelid et al.10 found an association of anti-CCP with ESR
nd CRP levels and with DAS28. On the other hand, Nell et al.9
oticed a worse therapeutic response in DAS28 in seroposi-
ive patients after 5 and 10 years of follow-up; nevertheless,
his result did not achieve statistical signiﬁcance. In estab-
ished RA, disease activity relates irregularly with anti-CCP
ositivity.19,20,23
Our study found no association between anti-CCP and
AQ. Functional disability in early RA, assessed by HAQ,
eems not to be associated with the presence of anti-CCP.24,26
he same result has been reported in established RA.19,23
n their evaluation of the association of anti-CCP with a
apanese version of HAQ, Shidara et al.28 found a signiﬁ-
ant association; but the higher degree of disability resulting
rom a 20-year mean duration of disease challenges an inde-
endent association between the antibody and functional
utcomes of RA. In Brazil, Silva et al.18 studied 100 patients
ith established RA, with a mean of eight years of dis-
ase. These authors found an association between anti-CCP
26Please cite this article in press as: Porto LSS, et al. Anti-CCP antibodies 
magnetic resonance imaging study. Rev Bras Reumatol. 2015. http://dx.do
nd HAQ, while Mota et al., in their cross-sectional study
valuating 65 patients with early RA, found no such associa-
ion. 5;x  x x(x x):xxx–xxx 5
Radiographic analysis is considered one of the more  objec-
tive methods to assess severity of RA. The SvdH method,
although the most detailed and difﬁcult to implement, is con-
sidered the most sensitive and accurate tool in the detection
of small changes over time.43 Although the literature show
an association between the presence of anti-CCP and struc-
tural damage measured by CR in early RA,3–15 in the case
of established RA the results were not as conclusive.15–23 It
is noteworthy that most of these studies used the Larsen
or Sharp method in their radiographic evaluation. Håfström
et al.,44 in a prospective study examining the role of RF and
anti-CCP based on the radiological progression with the use
of the SvdH method in patients with early RA, according to
prednisolone use, found that RF and anti-CCP were predictors
of radiographic progression only in patients who did not use
steroids. Our work also did not establish an association of anti-
CCP with structural damage, as assessed by SvdH in estab-
lished RA cases, which is in accordance with Håfström et al.’s
study, since 87.5% of our patients were still being medicated
with prednisone. On the other hand, Gandjbakhch et al.,45
in a prospective study which analyzed the factors involved
with radiographic progression (SvdH) in a group of patients
in remission and showing low disease activity, also found no
signiﬁcant association between anti-CCP and structural dam-
age. The mean structural damage index in our sample was
much lower, when compared to other studies in patients with
established RA with the use of SvdH method.19,21 This sug-
gests that our sample consisted of patients with less severe
and erosive disease and/or with a good response to therapeutic
intervention.
To the best of our knowledge, this study is the ﬁrst to exam-
ine the association of anti-CCP with structural damage in RA
as measured by MRI. Our results showed no statistically signif-
icant differences in the parameters evaluated by MRI among
anti-CCP positive and negative patients. In comparison with
other studies,46,47 we found lower values for the RAMRIS score
for synovitis, bone edema and erosion, indicating once again
that our sample was composed of a majority of individuals
with a milder and less erosive disease. It is noteworthy that
the use of MRI  for monitoring treatment with biological agents
can select high disease activity patients.
Patients in remission and showing low disease activity
can, in spite of clinical control, exhibit signs of activity on
MRI,48,49 and these changes may determine a future radio-
graphic progression.50 The results of this study indicated no
association between disease activity and RAMRIS scores. On
the other hand, 92.1% of our patients who were in remission or
in low disease activity showed signs of inﬂammation (edema
and synovitis) on MRI, although only two of them (16.6%)
had a synovitis >5 mm.  According to Gandjbakhch et al.,45 in
patients in remission or with low activity disease, only the
synovitis index of RAMRIS is associated with radiographic pro-
gression, with a cutoff point of 5 mm.  Thus, it is believed that
84% of our patients in remission and with low disease activ-
ity are protected. It is suggested that patients in remission or
with low disease activity, but with a synovitis >5 mm on MRI,
exhibit the same potential of radiographic evolution; thus,are not a marker of severity in established rheumatoid arthritis: a
i.org/10.1016/j.rbre.2015.07.018
these patients must be monitored in the same way, regardless
of anti-CCP presence.
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16  r e v b r a s r e u m a t o
In conclusion, in the sample investigated the results did not
establish an association of anti-CCP with disease severity. The
presence of confounding variables, such as an early diagnosis
and an appropriate response to therapeutic intervention, con-
tributed to setting up a group of patients with less severe and
slightly erosive disease. It is believed that the way of selecting
participants in our study (only individuals under 10 years of
disease duration and without difﬁculty to meet the research
protocol were accepted) may also have limited the exposure
of the entire universe of RA. None the less, this result allows
us to question if anti-CCP would have less inﬂuence on prog-
nosis for patients with a more  favorable disease proﬁle. On
the other hand, due to the small sample size, this study may
have failed to detect the most signiﬁcant differences. There-
fore, it is believed that the evaluation of a larger number of
individuals, possibly with a multicentric distribution in long-
term prospective observational studies and, if possible, with
greater control of confounding variables, could contribute to
the ultimate resolution of this issue. To date, we cannot sup-
port the indication for anti-CCP determination as a prognostic
tool in established RA.
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